There’s a question almost every Colorado patient brings into Monday Medical right now: Is tirzepatide actually better than semaglutide? Both are powerful GLP-1 therapies. Both work. The right one depends entirely on your biology — not a headline.
Semaglutide and tirzepatide are both GLP-1 receptor agonists — they mimic a gut hormone that signals fullness to your brain, slows gastric emptying, and stabilizes blood sugar after meals.
The difference: tirzepatide goes one step further. It also activates GIP receptors (glucose-dependent insulinotropic polypeptide), a second gut hormone that enhances fat metabolism and improves insulin sensitivity. This dual-action mechanism is why tirzepatide has shown stronger average weight loss in clinical trials. But “stronger on average” doesn’t mean “better for you specifically.”
The key distinction: Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 + GIP). Both significantly reduce appetite, slow digestion, and improve blood sugar control. The dual mechanism of tirzepatide appears to produce greater average weight loss — but individual responses vary far more than trial averages suggest.
Both drugs have produced remarkable results in large-scale randomized controlled trials. Here’s what the data actually says:
Average body weight reduction over 68 weeks with 2.4mg weekly semaglutide. Nearly 1 in 3 participants lost more than 20% of body weight. Significant cardiovascular and metabolic benefits observed.
Average body weight reduction at the highest dose (15mg weekly) over 72 weeks. Over half of participants achieved 20%+ weight loss. Fastest-approved drug for obesity in FDA history.
The takeaway isn’t that tirzepatide “wins.” It’s that both offer transformative results — and individual responses vary significantly more than trial averages suggest. Some patients respond exceptionally well to semaglutide. Others plateau on semaglutide and accelerate on tirzepatide.
The landmark SELECT trial (NEJM, 2023) demonstrated that semaglutide reduced major cardiovascular events by 20% in non-diabetic overweight patients — independent of weight loss. GLP-1 therapy is increasingly understood as metabolic medicine, not just a weight loss tool. Similar cardiovascular data is emerging for tirzepatide.
Several factors shape which therapy fits best. At Monday Medical, we evaluate all of these before recommending either drug:
“Your biology — not a headline or a trial average — should guide which GLP-1 is right for you. Both drugs work. The difference is matching the mechanism to the person.” Monday Medical — GLP-1 Program
At Monday Medical, we don’t prescribe GLP-1s one-size-fits-all. We start with a thorough evaluation of your metabolic health, hormone levels, goals, and history — then build a personalized protocol around you. Whether semaglutide or tirzepatide is the right fit, you’ll have ongoing monitoring, dose adjustments, and a care team that stays with you through every phase of the journey. We also offer both injectable and oral options — your call, with our guidance. And because hormone optimization has a measurable impact on GLP-1 response and lean muscle preservation, we look at the full picture, not just the medication.
Both semaglutide and tirzepatide represent a genuine leap forward in metabolic medicine. The goal at Monday Medical is to use the right tool, at the right dose, within the right overall protocol for your body. That’s how you get results that last — not just for the duration of a clinical trial, but for your actual life.
Schedule a free consultation at Monday Medical. We’ll evaluate your metabolic health, hormone levels, and goals — then build a personalized GLP-1 protocol around you.
Book Your Free Consultation →
